

Table 1. Expression of somatostatin receptors subtypes in non-medullary thyroid cancer: studies from the literature with more than 5 malignant thyroid tumours

Authors	Thyroid tumours evaluated	Methods	Somatostatin receptors detected
Pazaitou-Panayiotou et al 2012 ⁵	47 (38 PCs, 4 FCs, 2 ACs, 3 HCCs)	Immunohistochemistry for all SSTRs subtypes	SSTR 2 and 3 were expressed in all non-medullary thyroid carcinomas, SSTR 1 and 5 in 75% and SSTR 4 in 38%. The expression of SSTRs subtypes in normal thyroid tissue was low or absent.
Müssig et al 2012 ⁷	93 (67 PCs, 26 FCs)	Immunohistochemistry for all SSTRs subtypes	SSTR 1 to 5 were detected in 15% to almost 30% of thyroid tumours.
Sancak et al 2010 ⁶	17 PCs	Immunohistochemistry for SSTR 2	SSTR subtype 2 was expressed in PCs.
Klagge et al 2010 ⁸	45 (20 PCs, 20 FCs, 5 ACs)	mRNA expression for SSTRs	Thyroid tumours showed a predominant expression of SSTR 2 and SSTR 5, and a weak expression of SSTR 1 and SSTR 3.
Druckenthaner et al 2007 ⁹	17	mRNA expression for SSTRs correlated with immunochemistry for SSTR2	Thyroid tumours expressed SSTR 2, and less predominantly SSTR 3 and 5.
Forssell-Aronsson et al 2000 ¹⁰	9 PCs and 2 HCCs	mRNA expression	All thyroid tumours regularly expressed SSTR 1, 3, 4, and 5. SSTR 2 was not detected in PCs and was irregularly expressed in HCCs.
Ain et al 1997 ¹¹	Cell lines derived from 2 PCs, 2 FCs and 4 ACs	mRNA expression for SSTRs in thyroid cancer cell lines	Most thyroid cancer cell lines expressed SSTR 3 and 5.

PCs: papillary carcinomas; FCs: follicular carcinomas; ACs: anaplastic carcinomas; HCCs: Hürthle cell carcinomas; SSTRs: somatostatin receptors.